ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis [PDF]
TrialsBackground The standard of care (SOC) treatment for drug-susceptible pulmonary tuberculosis (DS-TB) consists of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE).
Linda J. Harrison +26 more
doaj +2 more sources
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques [PDF]
npj Antimicrobials and ResistanceTuberculosis (TB) killed approximately 1.3 million people in 2022 and remains a leading cause of death from the bacteria Mycobacterium tuberculosis (M.tb); this number of deaths was surpassed only by COVID-19, caused by the SARS-CoV-2 virus. The alarming
Hazem F. M. Abdelaal +16 more
doaj +2 more sources
Comparative In Vitro Drug Susceptibility Study of Five Oxazolidinones Against Mycobacterium tuberculosis in Hainan, China [PDF]
PathogensOxazolidinones, novel synthetic antibacterials, inhibit protein biosynthesis and show potent activity against Gram-positive bacteria, including Mycobacterium tuberculosis (MTB).
Jinhui Dong +9 more
doaj +2 more sources
Tuberculosis: Development of New Drugs and Treatment Regimens
Jurnal Respirasi, 2021 Tuberculosis (TB) still becomes a public health crisis. Drug-resistant TB (DR-TB) becomes a concern as the increasing DR-TB cases in countries with high TB burden.
Soedarsono Soedarsono
doaj +2 more sources
Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis [PDF]
Disease Models & Mechanisms, 2015 Mice are the most commonly used species for non-clinical evaluations of drug efficacy against tuberculosis (TB). Unlike commonly used strains, C3HeB/FeJ mice develop caseous necrosis in the lung, which might alter the representation of drug efficacy in a
Jean-Philippe Lanoix +2 more
doaj +2 more sources
Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli
International Journal of Mycobacteriology, 2017 Current tuberculosis (TB) treatment requires 6 months of combination therapy with isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol for active TB and 9 months of INH or 3 months of rifapentine (RFP) + INH for latent TB.
Angelo Iacobino +4 more
doaj +2 more sources
Sutezolid Liposomal Formulations to Tackle Mycobacterial Infection.
, 2023 Margarida Borges
core +3 more sources
In Vitro efficacy comparison of linezolid, tedizolid, sutezolid and delpazolid against rapid growing Mycobacteria isolated in Beijing, China [PDF]
Infection and Drug Resistance, 2020 ABSTRACT The natural resistance of rapid growth Mycobacterium (RGM) against multiple antibiotics renders the treatment of caused infections less successful and time consuming. Therefore, new effective agents are urgently needed.
Shuan Wen +9 more
openaire +7 more sources
Mycobacterium tuberculosis: Pathogenesis and therapeutic targets
MedComm, Volume 4, Issue 5, October 2023., 2023 In this review, we summarize the pathogenesis of TB infection, therapeutic targets, and corresponding modulators, including first‐line medications, current clinical trial drugs and molecules in preclinical assessment. Our review provides valuable insights for future antituberculosis drug development efforts.
Jiaxing Yang +3 more
wiley +1 more source
Advances in Key Drug Target Identification and New Drug Development for Tuberculosis
BioMed Research International, Volume 2022, Issue 1, 2022., 2022 Tuberculosis (TB) is a severe infectious disease worldwide. The increasing emergence of drug‐resistant Mycobacterium tuberculosis (Mtb) has markedly hampered TB control. Therefore, there is an urgent need to develop new anti‐TB drugs to treat drug‐resistant TB and shorten the standard therapy.
Jie Mi +3 more
wiley +1 more source